Sara A. De La Fuente

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications

Long-acting cabotegravir and rilpivirine in people with HIV and obesity: Real-world outcomes from the RELATIVITY cohort.

Long-acting cabotegravir and rilpivirine in people with HIV and obesity: Real-world outcomes from the RELATIVITY cohort.

Journal: HIV medicine
Published: November 19, 2025

Drug Addiction in Gay and Bisexual Men Living with HIV Engaged in Sexualized Drug Use: Recent Drug Use, Polydrug and Depressive Symptoms as Predictors.

Drug Addiction in Gay and Bisexual Men Living with HIV Engaged in Sexualized Drug Use: Recent Drug Use, Polydrug and Depressive Symptoms as Predictors.

Journal: AIDS and behavior
Published: March 19, 2025

Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial.

Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial.

Journal: The lancet. HIV
Published: February 18, 2025

Patterns of Sexualized Drug Use among Gay, Bisexual, and Other Men Who Have Sex with Men Living with HIV: Insights from a Comprehensive Study-The U-SEX-2 GESIDA 9416 Study.

Patterns of Sexualized Drug Use among Gay, Bisexual, and Other Men Who Have Sex with Men Living with HIV: Insights from a Comprehensive Study-The U-SEX-2 GESIDA 9416 Study.

Journal: Journal of clinical medicine
Published: August 28, 2023

Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV.

Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV.

Journal: Viruses
Published: March 11, 2023

Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study.

Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study.

Journal: Medicine
Published: November 12, 2021

Different HCV Exposure Drives Specific miRNA Profile in PBMCs of HIV Patients.

Different HCV Exposure Drives Specific miRNA Profile in PBMCs of HIV Patients.

Journal: Biomedicines
Published: September 16, 2021

Severe Lymphopenia as a Predictor of COVID-19 Mortality in Immunosuppressed Patients.

Severe Lymphopenia as a Predictor of COVID-19 Mortality in Immunosuppressed Patients.

Journal: Journal of clinical medicine
Published: July 13, 2021

Bacterial infections in patients hospitalized with COVID-19.

Bacterial infections in patients hospitalized with COVID-19.

Journal: Internal and emergency medicine
Published: May 19, 2021

Major determinants of death in patients hospitalized with COVID-19 during the first epidemic wave in Madrid, Spain.

Major determinants of death in patients hospitalized with COVID-19 during the first epidemic wave in Madrid, Spain.

Journal: Medicine
Published: September 25, 2020

TLR9-1486C/T polymorphism is associated with hepatocellular carcinoma recurrence after liver transplantation.

TLR9-1486C/T polymorphism is associated with hepatocellular carcinoma recurrence after liver transplantation.

Journal: Biomarkers in medicine
Published: July 19, 2019

Drug-related and psychopathological symptoms in HIV-positive men who have sex with men who inject drugs during sex (slamsex): Data from the U-SEX GESIDA 9416 Study.

Drug-related and psychopathological symptoms in HIV-positive men who have sex with men who inject drugs during sex (slamsex): Data from the U-SEX GESIDA 9416 Study.

Journal: PloS one
Published: July 06, 2019
Showing 1-12 of 18

Last Updated: 09/26/2026